2 research outputs found
Gluten-dependent intestinal autoimmune response
Celiac disease is a multisystemic autoimmune disease of the small bowel induced in genetically subjects by the gluten. High specific and gluten-dependent production of autoantibodies targeting self-proteins of the transglutaminase family are synthesized only at the intestinal mucosa. These anti-transglutamimnase antibodies are found deposited in intestinal and extraintestinal tissue where they might exert an adverse biological effects, together with the intestinal mucosal gliadin-specific T lymphocytes. Here we report a brief review article of anti-transglutaminase antibodies effects discussing their roles in the pathogenesis of several clinical manifestations of the celiac disease
A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects
The multifunctional, protein cross-linking transglutaminase 2 (TG2) is the main autoantigen in celiac disease, an autoimmune disorder with defined etiology. Glutamine-rich gliadin peptides from ingested cereals, after their deamidation by TG2, induce T-lymphocyte activation accompanied by autoantibody production against TG2 in 1-2% of the population. The pathogenic role and exact binding properties of these antibodies to TG2 are still unclear. Here we show that antibodies from different celiac patients target the same conformational TG2 epitope formed by spatially close amino acids of adjacent domains. Glu153 and 154 on the first alpha-helix of the core domain and Arg19 on first alpha-helix of the N-terminal domain determine the celiac epitope that is accessible both in the closed and open conformation of TG2 and dependent on the relative position of these helices. Met659 on the C-terminal domain also can cooperate in antibody binding. This composite epitope is disease-specific, recognized by antibodies derived from celiac tissues and associated with biological effects when passively transferred from celiac mothers into their newborns. These findings suggest that celiac antibodies are produced in a surface-specific way for which certain homology of the central glutamic acid residues of the TG2 epitope with deamidated gliadin peptides could be a structural basis. Monoclonal mouse antibodies with partially overlapping epitope specificity released celiac antibodies from patient tissues and antagonized their harmful effects in cell culture experiments. Such antibodies or similar specific competitors will be useful in further functional studies and in exploring whether interference with celiac antibody actions leads to therapeutic benefits